170 related articles for article (PubMed ID: 28339027)
21. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.
Marchiani S; Bonaccorsi L; Ferruzzi P; Crescioli C; Muratori M; Adorini L; Forti G; Maggi M; Baldi E
J Cancer Res Clin Oncol; 2006 Jun; 132(6):408-16. PubMed ID: 16485114
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
24. Embelin-Induced Apoptosis of Human Prostate Cancer Cells Is Mediated through Modulation of Akt and β-Catenin Signaling.
Park N; Baek HS; Chun YJ
PLoS One; 2015; 10(8):e0134760. PubMed ID: 26252009
[TBL] [Abstract][Full Text] [Related]
25. Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin.
Wei YB; Guo Q; Gao YL; Yan B; Wang Z; Yang JR; Liu W
Mol Med Rep; 2015 Jul; 12(1):226-32. PubMed ID: 25684730
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
Cheng L; Zang J; Dai HJ; Li F; Guo F
Int J Oncol; 2018 Jul; 53(1):203-214. PubMed ID: 29693147
[TBL] [Abstract][Full Text] [Related]
27. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.
Lu B; Geng L; Musiek A; Tan J; Cao C; Donnelly E; McMahon G; Choy H; Hallahan DE
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):844-50. PubMed ID: 14967441
[TBL] [Abstract][Full Text] [Related]
28. [Crypotanshione reduces the expression of metadherin in DU145 prostate cancer cells].
Yao Y; Li HZ; Qian BJ; Liu CM; Zhang JB; Lin MC
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):782-7. PubMed ID: 26552209
[TBL] [Abstract][Full Text] [Related]
29. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
31. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
Machida S; Saga Y; Takei Y; Mizuno I; Takayama T; Kohno T; Konno R; Ohwada M; Suzuki M
Int J Cancer; 2005 Mar; 114(2):224-9. PubMed ID: 15551349
[TBL] [Abstract][Full Text] [Related]
33. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
34. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
35. SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression.
Wang L; Liu Z; Ma D; Piao Y; Guo F; Han Y; Xie X
Cancer Cell Int; 2013 Aug; 13(1):88. PubMed ID: 23984913
[TBL] [Abstract][Full Text] [Related]
36. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells.
Benitez A; Yates TJ; Lopez LE; Cerwinka WH; Bakkar A; Lokeshwar VB
Cancer Res; 2011 Jun; 71(12):4085-95. PubMed ID: 21555367
[TBL] [Abstract][Full Text] [Related]
37. Tetrandrine suppresses metastatic phenotype of prostate cancer cells by regulating Akt/mTOR/MMP-9 signaling pathway.
Kou B; Liu W; He W; Zhang Y; Zheng J; Yan Y; Zhang Y; Xu S; Wang H
Oncol Rep; 2016 May; 35(5):2880-6. PubMed ID: 26935264
[TBL] [Abstract][Full Text] [Related]
38. [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
Wang YX; Shi YH; Gong LH; Li Y; Heng WJ; You JF; Zhong HH; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):681-6. PubMed ID: 18194602
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
Tokuyama J; Kubota T; Saikawa Y; Yoshida M; Furukawa T; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2005; 25(1A):17-22. PubMed ID: 15816514
[TBL] [Abstract][Full Text] [Related]
40. MHY-449, a novel dihydrobenzofuro[4,5-b][1,8] naphthyridin-6-one derivative, induces apoptotic cell death through modulation of Akt/FoxO1 and ERK signaling in PC3 human prostate cancer cells.
Lee SH; Kang YJ; Sung B; Kim DH; Lim HS; Kim HR; Kim SJ; Yoon JH; Moon HR; Chung HY; Kim ND
Int J Oncol; 2014 Mar; 44(3):905-11. PubMed ID: 24424889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
